News & Events

Date Title  
06/10/19
Experienced executive with successful track record of leading strategic growth initiatives, including national chain of retail cosmetic surgery clinics SAN DIEGO , June 10, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the
06/04/19
Expands the Company’s intellectual property estate to 20 issued US patents SAN DIEGO , June 04, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon
05/23/19
SAN DIEGO , May 23, 2019 (GLOBE NEWSWIRE) -- OBALON THERAPEUTICS, INC. (NASDAQ: OBLN) (“Obalon” or the “Company”) , a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today
05/21/19
Results from over 1,400 patients treated across 143 sites with Obalon’s non-surgical weight loss solution continue to affirm the safety and effectiveness of the Obalon Balloon System SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc.
05/17/19
SAN DIEGO , May 17, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it received two written
04/11/19
SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that the Company has retained
04/03/19
SAN DIEGO , April 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced an organizational
03/14/19
SAN DIEGO , March 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang ,
02/27/19
SAN DIEGO , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ) announces the first commercial use of the Obalon Navigation System™ and Touch™ Inflation Dispenser for balloon administration. The Obalon Navigation System and Touch Inflation Dispenser are intended to improve
02/22/19
Obalon Navigation System™ with Touch™ Inflation Dispenser are intended to increase adoption of the Obalon Balloon by improving ease of administration and eliminating the need for x-ray imaging on placement SAN DIEGO , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc.
02/22/19
SAN DIEGO , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial
02/15/19
SAN DIEGO , Feb. 15, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release
01/03/19
SAN DIEGO , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, promotes Amy VandenBerg to Chief
01/02/19
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to host a
01/02/19
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today completed the succession plan
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling